NeuroVigil closed a $6 billion Series B deal with 27 strategic investors, valuing the company at over $6 billion
NeuroVigil closed a $6 billion Series B deal with 27 strategic investors, valuing the company at over $6 billion
04/06/24, 4:19 AM
Location
san franciscoMoney raised
$85 million
Industry
biotechnology
health care
Round Type
series b
Investors
7 Top Law Firms, 5 Pioneering Clinics, 3 Elite Vcs, American Super Angel, Leading University, Major Hospital
NeuroVigil has closed a $6 billion Series B deal, marking the highest Series B financing in history. The funding round included 27 strategic investors and valued the company at over $6 billion. The company's non-invasive iBrain™ Personal Brain Monitor has been launched in 4 US states with plans for further development and applications.
Company Info
Location
san francisco, california, united states
Additional Info
Silicon Valley-based Neurotechnology Powerhouse, NeuroVigil focuses on developing non-invasive brain technology to monitor brain activity and detect potential health issues. The company holds numerous patents in the field of neurotechnology and has secured partnerships with major pharmaceutical companies for research and development.